State Of Wyoming Atea Pharmaceuticals, Inc. Transaction History

State Of Wyoming

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$3.0 - $4.97 $21,039 - $34,854	-7,013 Reduced 21.98%	24,893 $83,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $138,791 - $196,860	31,906 New	31,906 $153,000
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $25,051 - $38,446	-4,700 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.5 - $9.19 $25,850 - $43,193	4,700 New	4,700 $34,000
Q4 2021 Feb 11, 2022	SELL	$7.67 - $44.59 $352 - $2,051	-46 Closed	0 $0
Q3 2021 Feb 11, 2022	SELL	$21.33 - $35.06 $6,590 - $10,833	-309 Reduced 87.04%	46 $2,000
Q2 2021 Feb 11, 2022	BUY	$19.22 - $59.08 $1,633 - $5,021	85 Added 31.48%	355 $8,000
Q1 2021 Feb 08, 2022	BUY	$41.42 - $88.44 $11,183 - $23,878	270 New	270 $17,000

109

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $255M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.